Metformin may protect beta-cell function and insulin secretion capacity by relieving glucotoxicity and lipotoxicity

Shangyu CHEN, Zhe DAI, Huawei WANG, Yancheng XU

Abstract


Objective: To investigate the protective effect of metformin on beta cells. Methods NIT-1 cells were treated with high glucose and/or palmitate pretreatment, with/without metformin. Cell apoptosis, intracellular reactive oxygen species (ROS) production and glucose-stimulated insulin secretion were measured. Cleaved caspase-3, cleaved caspase-9, and p-JNK were measured to evaluated apoptosis and activation of the ER stress pathway. Results (1) The addition of metformin may partly reverse the impairment of insulin secretion in NIT-1 cells with high glucose and/or palmitate. (2) After metformin pre-treatment, ROS production and cell apoptosis were significantly decreased in NIT-1 cells treated with palmitate and/or high glucose. (3) After metformin pretreatment, expression of cleaved caspase 3, cleaved caspase 9, and p-JNK were significantly decreased in NIT-1 cells treated with palmitate and/or high glucose, in consistence with the decreased apoptosis after metformin pretreatment in NIT-1 cells. Conclusion Metformin may help to decrease glucose variability and preserve beta-cell function. The mechanism may be related to decreases in oxidative stress and ER stress induced by glucotoxicity and lipotoxicity.

References


Baidwan S, Chekuri A, Hynds DL, Kowluru A (2017). Glucotoxicity promotes aberrant activation and mislocalization of Ras-related C3 botulinum toxin substrate 1 [Rac1] and metabolic dysfunction in pancreatic islet β-cells: reversal of such metabolic defects by metformin. Apoptosis. 22(11):1380-1393.

Bi Y, Tong GY, Yang HJ, Cai MY, Ma JH, Liang J, Xin B, Miao H, Peng ZH, Zhu DL (2011). The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. Diabetes-Metabolism Research and Reviews. 29(8):664-72.

Cen J, Sargsyan E, Forslund A, Bergsten P (2018). Mechanisms of beneficial effects of metformin on fatty acid-treated human islets. Journal of Molecular Endocrinology. 61(3):91-99

Cheng Q, Yang S, Zhao C, Wang Z, Feng Z, Li R, Ye P, Zhang S, Deng H, Zhou B, Long J, Gong L, Qing H, Luo C, Li Q (2015). Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy. Journal of Diabetes. 7(2):182-91.

Cho YM, Kieffer TJ (2011). New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia. 54(2):219-22.

Dai YL, Huang SL, Leng Y (2015). AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic β-cell Apoptosis via Differential Downstream Mechanisms. International Journal of Biological Sciences. 11(11):1272-80.

Fang FS, Gong YP, Li CL, Li J, Tian H, Huang W, Wang LC, Li L (2014). Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus. European Journal of Endocrinology. 170(6):901-8.

Gregg B, Elghazi L, Alejandro EU, Smith MR, Blandino-Rosano M, El-Gabri D, Cras-Méneur C, Bernal-Mizrachi E (2014). Exposure of mouse embryonic pancreas to metformin enhances the number of pancreatic progenitors. Diabetologia. 57(12):2566-75.

Gregg BE, Botezatu N, Brill JD, Hafner H, Vadrevu S, Satin LS, Alejandro EU, Bernal-Mizrachi E (2018). Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring. Science Report. 8(1):5745.

Hashemitabar M, Bahramzadeh S, Saremy S, Nejaddehbashi F (2015). Glucose plus metformin compared with glucose alone on β-cell function in mouse pancreatic islets. Biomedical Reports. 3(5):721-725.

Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y (2013). Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technology & Therapeutics. 15(10):859-69.

Jiang Y, Huang W, Wang J, Xu Z, He J, Lin X, Zhou Z, Zhang J (2014). Metformin plays a dual role in MIN6 pancreatic β cell function through AMPK-dependent autophagy. International Journal of Biological Sciences. 10(3):268-77.

Jung TW, Lee MW, Lee YJ, Kim SM (2012). Metformin prevents endoplasmic reticulum stress-induced apoptosis through AMPK-PI3K-c-Jun NH2 pathway. Biochemical and Biophysical Research Communications. 417(1):147-52.

Kim HI, Lee JS, Kwak BK, Hwang WM, Kim MJ, Kim YB, Chung SS (2019). Metformin Ameliorates Lipotoxic β-Cell Dysfunction through a Concentration-Dependent Dual Mechanism of Action. Diabetes & Metabolism Journal; 43: 1-13

Langelueddecke C, Jakab M, Ketterl N, Lehner L, Hufnagl C, Schmidt S, Geibel JP, Fuerst J, Ritter M (2012). Effect of the AMP-kinase modulators AICAR, metformin and compound C on insulin secretion of INS-1E rat insulinoma cells under standard cell culture conditions. Cellular Physiology Biochemistry. 29(1-2):75-86.

Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, Yoon JW, Kang SM, Choi SH, Cho YM, Park KS, Jang HC (2012). Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clinical Endocrinology (Oxf). 77(2):215-23.

Liu C, Wu D, Zheng X, Li P, Li L (2015). Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technology & Therapeutics. 17(2):142-8.

Liu W, Yang XJ (2016). The effect of metformin on adolescents with type 1 diabetes: A systematic review and meta-Analysis of randomized controlled trials. International Journal of Endocrinology. 2016: 1-12

Lundquist I, Mohammed Al-Amily I, Meidute Abaraviciene S, Salehi A (2016). Metformin ameliorates dysfunctional traits of glibenclamide- and glucose-induced insulin secretion by suppression of imposed overactivity of the islet nitric oxide synthase-NO System. PLoS One. 11(11):e0165668.

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S (2016). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Annals of Internal Medicine. 164(11):740-51.

Moon JS, Karunakaran U, Elumalai S, Lee IK, Lee HW, Kim YW, Won KC (2017). Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells. Journal of Diabetes Complications. 31(1):21-30.

Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T (2009). Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. Journal of Diabetes Science and Technology. 3(6):1442-50.

Out M, Miedema I, Jager-Wittenaar H, van der Schans C, Krijnen W, Lehert P, Stehouwer C, Kooy A (2018). Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. Diabetes Obesity and Metabolism. 20(1):219-223.

Pan QR, Li WH, Wang H, Sun Q, Xiao XH, Brock B, Schmitz O (2009). Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell. Hormone and Metabolic Research. 41(11):799-804.

Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F (2000). Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. May;49(5):735-40.

Piro S, Rabuazzo AM, Renis M, Purrello F (2012). Effects of metformin on oxidative stress, adenine nucleotides balance, and glucose-induced insulin release impaired by chronic free fatty acids exposure in rat pancreatic islets. Journal of Endocrinological Investigation. 35(5):504-10.

Quan H, Zhang H, Wei W, Fang T, Chen D, Chen K (2017). A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Experimental and Therapeutic Medicine. 14(4):3279-3287.

Retnakaran R, Choi H, Ye C, Kramer CK, Zinman B (2018). Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes. Diabetes Obesity & Metabolism. 20(6):1399-1407.

Richardson H, Campbell SC, Smith SA, Macfarlane WM (2006). Effects of rosiglitazone and metformin on pancreatic beta cell gene expression. Diabetologia. 49(4):685-96.

Simon-Szabó L, Kokas M, Mandl J, Kéri G, Csala M (2014). Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS One. 9(6): e97868.

Tajima K, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Togashi Y, Terauchi Y (2017). Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. American Journal of Physiology-Endocrinology and Metabolism. 313(3):E367-E380.

Tao T, Wu P, Wang Y, Liu W (2018). Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC Endocrine Disorders. 18(1):14.

Vellanki P, Smiley DD, Stefanovski D, Anzola I, Duan W, Hudson M, Peng L, Pasquel FJ, Umpierrez GE (2016). Randomized controlled study of metformin and sitagliptin on long-term normoglycemia remission in African-American patients with hyperglycemic crises. Diabetes Care. 39(11):1948-1955.

Wang Q, Cai Y, Van de Casteele M, Pipeleers D, Ling Z (2011). Interaction of glibenclamide and metformin at the level of translation in pancreatic β cells. Journal of Endocrinology. 208(2):161-9.

Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ (2012). Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obesity & Metabolism. 14(1):67-76.

Wulffelé MG, Kooy A, Lehert P, Bets D, Oom JA, Borger van der Burg B, Donker AJ, Stehouwer CD (2002). Discontinuation of metformin in type 2 diabetes patients treated with insulin. Netherland Journal of Medicine. 60(6):249-52.

Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD (2002). Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 25(12):2133-40.

Zhang Y, Zhao Z, Wang S, Zhu W, Jiang Y, Sun S, Chen C, Wang K, Mu L, Cao J, Zhou Y, Gu W, Hong J, Wang W, Ning G (2017). Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes. Diabetes-Metabolism Research and Reviews. 33(7).322-333


Refbacks

  • There are currently no refbacks.